Nemaline Myopathy 10 (NEM10) Cell Models for Research

Nemaline myopathy (NM) is a rare congenital myopathy with an estimated incidence of 1 in 50,000 live births worldwide (WHO, 2023). NEM10 is a specific subtype caused by mutations in the KLHL40 gene, accounting for approximately 5-10% of all NM cases. The disease presents with severe hypotonia, muscle weakness, and respiratory insufficiency in infancy, leading to high mortality in the first year of life. According to NCI SEER data, the 5-year survival for severe congenital myopathies is less than 50%, but for NEM10 specifically, survival beyond infancy is rare without respiratory support. The clinical burden is significant, with most affected individuals requiring long-term ventilation and feeding support.

NEM10 is an ideal model for studying muscle development and contractile function due to its well-defined genetic basis and the availability of patient-derived cell lines. The disease is caused by loss-of-function mutations in KLHL40, which encodes a protein involved in sarcomere assembly. Research on NEM10 can provide insights into fundamental mechanisms of muscle protein turnover and the role of ubiquitin ligases in myofibrillogenesis. Open questions include the precise molecular pathways leading to nemaline rod formation and the potential for targeted therapies. Gene-edited cell models, such as KLHL40 knockout myoblasts, are valuable tools for investigating these mechanisms and screening potential drugs.

The pathogenesis of NEM10 involves disruption of sarcomere assembly and protein degradation pathways. Key steps include:

1. KLHL40 mutations lead to loss of function of the KLHL40 protein, which is a substrate-specific adaptor for Cullin3-based E3 ubiquitin ligases.

2. This results in impaired ubiquitination and degradation of its targets, including NEB and MYOZ2.

3. Accumulation of these proteins disrupts the assembly of thin filaments in sarcomeres.

4. Consequently, muscle fibers develop nemaline rods, which are electron-dense structures composed of Z-disc proteins.

5. The resulting sarcomeric disorganization leads to muscle weakness and atrophy.

Data from TCGA and COSMIC indicate that KLHL40 mutations are the primary driver, with secondary alterations in sarcomeric genes contributing to phenotypic variability.

NEM10 involves deregulation of several signaling networks:

• • Ubiquitin-Proteasome System: KLHL40-Cullin3 complex is central; loss leads to accumulation of NEB and MYOZ2.
• • Actin Dynamics: Disrupted actin polymerization and thin filament assembly.
• • Calcium Signaling: Altered calcium handling due to sarcomeric disorganization.
• • Apoptosis: Increased apoptosis in muscle cells due to protein aggregation.

Key nodes include:

• • KLHL40
• • Cullin3
• • NEB
• • MYOZ2
• • ACTA1
• • TPM3

Organoids: 3D muscle organoids derived from iPSCs can recapitulate sarcomere assembly and are useful for studying NEM10 pathogenesis. They allow long-term culture and drug testing.

Animal models for NEM10 include:

• • Knockout mouse models: KLHL40 knockout mice exhibit muscle weakness and nemaline rods, mimicking the human phenotype.
• • Zebrafish models: Morpholino knockdown of klhl40 in zebrafish leads to muscle defects.
• • Patient-derived xenografts (PDX): Not commonly used for myopathies, but muscle cell xenografts can be used for in vivo studies.
• • Genetically engineered mouse models (GEMM): Conditional knockouts allow tissue-specific deletion.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise mutations in KLHL40. For example:

• • KLHL40 knockout myoblasts: Generated by introducing frameshift mutations in exon 2, resulting in loss of protein expression.
• • KLHL40 point mutation knock-in: Introducing a common pathogenic missense mutation (e.g., p.Arg320His) to study dominant-negative effects.

These models are sequence-verified and can be used for functional studies, drug screening, and mechanistic research. Commercially available, validated gene-edited cell lines accelerate research by providing consistent and reproducible models, but it is important to select appropriate controls (e.g., parental cell lines) to ensure specificity.

Gene-edited cell lines are essential for validating the role of KLHL40 in muscle biology. For example:

• • Knockout of KLHL40 in C2C12 cells leads to reduced myotube formation and altered expression of sarcomeric genes.
• • Knock-in of a pathogenic mutation can be used to study the impact on protein-protein interactions.
• • CRISPR screens can identify genetic modifiers that rescue the phenotype, providing new therapeutic targets.

Isogenic cell line pairs (wild-type vs. KLHL40 knockout) are powerful tools for high-throughput screening:

• • Screening for compounds that restore sarcomere assembly or reduce nemaline rod formation.
• • Testing drugs that enhance protein degradation pathways.
• • Modeling resistance to potential therapies by generating resistant cell lines through chronic exposure.

CRISPR-engineered cells can be used to identify biomarkers for NEM10:

• • Transcriptomic and proteomic profiling of KLHL40 knockout cells reveals differentially expressed genes and proteins.
• • Synthetic lethality screens can identify genes that are essential in the absence of KLHL40, which could serve as therapeutic targets.
• • Secreted proteins from mutant cells may serve as circulating biomarkers.